Emerg Infect Dis. 2005 Jul;11(7):1016-20.

SARS vaccine development.

Source

New York Blood Center, New York, New York 10021, USA. SJiang@NYBloodcenter.org

Abstract

Developing effective and safe vaccines is urgently needed to prevent infection by severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV). The inactivated SARS-CoV vaccine may be the first one available for clinical use because it is easy to generate; however, safety is the main concern. The spike (S) protein of SARS-CoV is the major inducer of neutralizing antibodies, and the receptor-binding domain (RBD) in the S1 subunit of S protein contains multiple conformational neutralizing epitopes. This suggests that recombinant proteins containing RBD and vectors encoding the RBD sequence can be used to develop safe and effective SARS vaccines.

PMID:: 16022774; [PubMed - indexed for MEDLINE]

Free full text

Publication Types, MeSH Terms, Substances

Publication Types

Review

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Labome Researcher Resource - ExactAntigen/Labome

Medical

Severe Acute Respiratory Syndrome - MedlinePlus Health Information

Supplemental Content

Related citations

Review Vaccine design for severe acute respiratory syndrome coronavirus. [Viral Immunol. 2005]
Review Vaccine design for severe acute respiratory syndrome coronavirus.
He Y, Jiang S. Viral Immunol. 2005; 18(2):327-32.
Antigenic and immunogenic characterization of recombinant baculovirus-expressed severe acute respiratory syndrome coronavirus spike protein: implication for vaccine design. [J Virol. 2006]
Antigenic and immunogenic characterization of recombinant baculovirus-expressed severe acute respiratory syndrome coronavirus spike protein: implication for vaccine design.
He Y, Li J, Heck S, Lustigman S, Jiang S. J Virol. 2006 Jun; 80(12):5757-67.
Identification and characterization of novel neutralizing epitopes in the receptor-binding domain of SARS-CoV spike protein: revealing the critical antigenic determinants in inactivated SARS-CoV vaccine. [Vaccine. 2006]
Identification and characterization of novel neutralizing epitopes in the receptor-binding domain of SARS-CoV spike protein: revealing the critical antigenic determinants in inactivated SARS-CoV vaccine.
He Y, Li J, Du L, Yan X, Hu G, Zhou Y, Jiang S. Vaccine. 2006 Jun 29; 24(26):5498-508. Epub 2006 May 11.
Identification of a critical neutralization determinant of severe acute respiratory syndrome (SARS)-associated coronavirus: importance for designing SARS vaccines. [Virology. 2005]
Identification of a critical neutralization determinant of severe acute respiratory syndrome (SARS)-associated coronavirus: importance for designing SARS vaccines.
He Y, Zhu Q, Liu S, Zhou Y, Yang B, Li J, Jiang S. Virology. 2005 Mar 30; 334(1):74-82.
Review Development of subunit vaccines against severe acute respiratory syndrome. [Drugs Today (Barc). 2008]
Review Development of subunit vaccines against severe acute respiratory syndrome.
Du L, He Y, Jiang S, Zheng BJ. Drugs Today (Barc). 2008 Jan; 44(1):63-73.

See reviews... See all...

Cited by 9 PubMed Central articles

Potent and persistent antibody responses against the receptor-binding domain of SARS-CoV spike protein in recovered patients. [Virol J. 2010]
Potent and persistent antibody responses against the receptor-binding domain of SARS-CoV spike protein in recovered patients.
Cao Z, Liu L, Du L, Zhang C, Jiang S, Li T, He Y. Virol J. 2010 Nov 4; 7:299. Epub 2010 Nov 4.
A 219-mer CHO-expressing receptor-binding domain of SARS-CoV S protein induces potent immune responses and protective immunity. [Viral Immunol. 2010]
A 219-mer CHO-expressing receptor-binding domain of SARS-CoV S protein induces potent immune responses and protective immunity.
Du L, Zhao G, Chan CC, Li L, He Y, Zhou Y, Zheng BJ, Jiang S. Viral Immunol. 2010 Apr; 23(2):211-9.
Review Potent human monoclonal antibodies against SARS CoV, Nipah and Hendra viruses. [Expert Opin Biol Ther. 2009]
Review Potent human monoclonal antibodies against SARS CoV, Nipah and Hendra viruses.
Prabakaran P, Zhu Z, Xiao X, Biragyn A, Dimitrov AS, Broder CC, Dimitrov DS. Expert Opin Biol Ther. 2009 Mar; 9(3):355-68.

See all...

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

SARS vaccine development.
SARS vaccine development.
Emerg Infect Dis. 2005 Jul ;11(7):1016-20.

PubMed
The challenge of mastitis.
The challenge of mastitis.
Arch Dis Child. 2003 Sep ;88(9):818-21.

PubMed
Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizo...
Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: a systematic review.
J Clin Psychopharmacol. 2008 Apr ;28(2):203-9.

PubMed
Bevacizumab beyond first progression is associated with prolonged overall surviv...
Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE).
J Clin Oncol. 2008 Nov 20 ;26(33):5326-34. Epub 2008 Oct 14 .

PubMed
Neurokinin-1 enables measles virus trans-synaptic spread in neurons.
Neurokinin-1 enables measles virus trans-synaptic spread in neurons.
Virology. 2007 May 25 ;362(1):235-44. Epub 2007 Apr 16 .

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Display Settings:

Send to: